The Anti-hEGFR isotype family features the variable region of cetuximab. Cetuximab is a chimeric human/mouse IgG1 monoclonal antibody that targets EGFR, a cell surface receptor overexpressed in many types of cancer. Binding of cetuximab to EGFR blocks ligand/receptor binding and induces receptor internalization and subsequent degradation. Cetuximab has been approved by the FDA for the treatment of metastatic colorectal cancer and metastatic squamous cell carcinoma of the head and neck.
InvivoGen's Anti-hEGFR isotype family has been generated by recombinant DNA technology, produced in CHO cells, and purified by affinity chromatography with protein G (IgG) or peptide M (IgA2).
